Clinical Trial Update: Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating ACTHar Gel alone or with tacrolimus for fibrillary glomerulopathy was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrillary Glomerulopathy
• Renal Disease

Drugs mentioned

• Acthar Gel (repository corticotropin injection)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: NephroNet, Inc. | Conditions: Renal Disease | Phase 4 | Status: WITHDRAWN